Screening for Abnormal Glucose Metabolism in Patients at Risk of Developing Diabetes
Compare Versions of: "Screening for Abnormal Glucose Metabolism in Patients at Risk of Developing Diabetes"
The Compare function compares two years of the measure specifications found in the header of the measure's HTML. It does not include a comparison of any information in the body of the HTML, e.g., population criteria, Clinical Quality Language, or value sets.
Strikethrough text highlighted in red indicates information changed from the previous version. Text highlighted in green indicates information updated in the new eCQM version.
Compare version to
| Measure Information | 2026 Performance Period |
|---|---|
| Title | Screening for Abnormal Glucose Metabolism in Patients at Risk of Developing Diabetes |
| CMS eCQM ID | CMS1154v1 |
| CBE ID* | Not Applicable |
| MIPS Quality ID | 515 |
| Measure Steward | American Medical Association (AMA) |
| Description |
Percentage of adult patients with risk factors for type 2 diabetes who are due for glycemic screening for whom the screening process was completed during the measurement period. |
| Measure Scoring | Proportion |
| Measure Type | Process |
| Stratification |
None |
| Risk Adjustment |
None |
| Rationale |
This measure is critical to identifying patients with prediabetes who may benefit from interventions to prevent type 2 diabetes and identification of undiagnosed type 2 diabetes. The Centers for Disease Control and Prevention (CDC) estimates that approximately 97.6 million American adults have prediabetes (CDC, 2024). They note that more than 80% of adults with prediabetes are not aware that they have the condition. Regular screening for prediabetes is a critical first step to helping patients avoid the disability and costs associated with progression to type 2 diabetes. The measure gives credit for three types of tests that can be used to detect abnormal glucose metabolism: HbA1c, oral glucose tolerance, and fasting plasma glucose. When considering which plasma glucose screening codes to include in the measure, the measure development team carefully considered two potential unintended consequences related to the limited use of accompanying fasting status codes. If the measure specified plasma glucose screening too narrowly, it could incentivize over screening, which would impose added burden on clinicians and increased costs to some patients. Alternatively, if the measure specified plasma glucose screening too broadly, it could give credit for non-fasting plasma glucose tests that are not adequate for diagnostic purposes. |
| Clinical Recommendation Statement |
The U.S. Preventive Services Task Force (USPSTF) recommends screening for prediabetes and type 2 diabetes in adults aged 35 to 70 years who have overweight or obesity. Clinicians should offer or refer patients with prediabetes to effective preventive interventions (B recommendation) (USPSTF, 2021). Evidence on the optimal screening interval for adults with an initial normal glucose test result is limited. Cohort and modeling studies suggest that screening every 3 years may be a reasonable approach for adults with normal blood glucose levels (USPSTF, 2021). Prediabetes and type 2 diabetes can be detected by measuring fasting plasma glucose or HbA1c level, or with an oral glucose tolerance test. A fasting plasma glucose level of 126 mg/dL (6.99 mmol/L) or greater, an HbA1c level of 6.5% or greater, or a 2-hour post-load glucose level of 200 mg/dL (11.1 mmol/L) or greater are consistent with the diagnosis of type 2 diabetes. A fasting plasma glucose level of 100 to 125 mg/dL (5.55-6.94 mmol/L), an HbA1c level of 5.7% to 6.4%, or a 2-hour post-load glucose level of 140 to 199 mg/dL (7.77-11.04 mmol/L) are consistent with prediabetes (USPSTF, 2021). |
| Improvement Notation |
Increased score indicates improvement - Higher score equals better quality |
| Definition |
None |
| Guidance |
The measure is limited to patients aged 35 to 70 with overweight or obesity because it is recommended that all patients with those risk factors be screened for diabetes at least once every three years. However, this measure is not intended to discourage screening at younger ages, which the USPSTF recommends considering for adults with overweight or obesity and any of the following risk factors: - Race/ethnicity with disproportionately high incidence and prevalence of diabetes (American Indian/Alaska Native, Asian American, Black, Hispanic/Latino, or Native Hawaiian/Pacific Islander persons) - Family history of diabetes - History of gestational diabetes - History of polycystic ovarian syndrome It is recommended that every patient evaluated by this measure also identify payer, race, ethnicity, and sex. This eCQM is a patient-based measure. This version of the eCQM uses QDM version 5.6. Please refer to the QDM page for more information on the QDM. |
| Initial Population |
All patients with at least two outpatient clinical encounters or one preventive clinical encounter during the measurement period who have the following risk factors for type 2 diabetes: - Most recent BMI ≥25 kg/m2 (BMI ≥23 kg/m2 for Asian patients) during measurement period, AND - Age 35-70 at start of measurement period. |
| Denominator |
All patients in the initial population. |
| Denominator Exclusions |
- Patient's pregnancy overlaps measurement period. - Patient with diagnosis of advanced illness or limited life expectancy overlaps measurement period. - Patient with diagnosis of diabetes overlaps 2-year look-back period. - Patient with diagnosis of prediabetes overlaps 2-year look-back period. - Patient with glycemic screening performed during 2-year look-back period. |
| Numerator |
Patients who had a glycemic screening test performed during the measurement period. |
| Numerator Exclusions |
None |
| Denominator Exceptions |
None |
| Telehealth Eligible | Yes |
| Next Version | No Version Available |
| Previous Version | No Version Available |